FierceBiotech 14 avr. 2026 Boehringer, Amgen discard early immunology candidates over lack of clinical potential
FierceBiotech 30 mars 2026 Viridian’s other rival to Amgen’s Tepezza scores phase 3 win, but investors need convincing
FierceBiotech 4 févr. 2026 Amgen advances toward lupus redemption while gastric cancer candidate struggles
FierceBiotech 30 janv. 2026 Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
FierceBiotech 13 janv. 2026 JPM26, Day 2: Amgen touts MariTide's showing in exploratory weight loss maintenance study
FierceBiotech 6 janv. 2026 Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs
FierceBiotech 11 déc. 2025 Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx